Compare CTRI & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRI | NKTR |
|---|---|---|
| Founded | 1909 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2024 | 1996 |
| Metric | CTRI | NKTR |
|---|---|---|
| Price | $20.54 | $74.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $29.88 | ★ $146.67 |
| AVG Volume (30 Days) | ★ 1.5M | 472.7K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,982,781,000.00 | $307,711,000.00 |
| Revenue This Year | $14.62 | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 13.10 | ★ 86.00 |
| 52 Week Low | $19.04 | $33.40 |
| 52 Week High | $42.99 | $109.00 |
| Indicator | CTRI | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 34.34 | 56.01 |
| Support Level | N/A | $64.99 |
| Resistance Level | $27.72 | $76.49 |
| Average True Range (ATR) | 0.73 | 3.07 |
| MACD | 0.04 | -0.31 |
| Stochastic Oscillator | 17.30 | 71.28 |
Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. Its reportable segments are: (i) U.S. Gas Utility Services (U.S. Gas); (ii) Canadian Utility Services (Canadian Operations); (iii) Union Electric Utility Services (Union Electric); and (iv) Non-Union Electric Utility Services (Non-Union Electric).
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.